Homocysteine
[Homocysteine ]
EPTIS factsheet 142635 | Last revision 2024-05-21 | URL: https://www.eptis.bam.de/pts142635 https://www.eptis.bam.de/pts142635
| PT provider | |||||||
| PT provider | Weqas Weqas | ||||||
| Based in | United Kingdom | ||||||
| Language(s) | |||||||
| Remarks | The Homocysteine programme is available as part of a comprehensive suite of programmes to assess and monitor the performance of the Clinical Biochemistry laboratory’s repertoire of both core and esoteric tests used for the diagnosis and monitoring of disease. Homocysteine is tested to aid in the diagnosis of homocysteinuria, as part of a “cardiovascular risk assessment” and to determine folate or vitamin B12-deficiency as blood homocysteine concentration can be raised in both conditions. Three liquid human serum samples with a range of concentrations found in both inborn errors and cardiovascular risk assessment are distributed on a bi-monthly basis. Eighteen samples are distributed annually which consist of endogenous samples along with a panel of linearly related samples produced from donations from healthy volunteers spiked with an exogenous source. The linearly related samples are distributed on a number of occasions over the year to assess both laboratory and method performance, including linearity, bias, within and between batch imprecision. Key Features: - Liquid human serum samples require no pre-analytical preparation. - Concentration cover in-born errors and cardiovascular risk range. - Includes endogenous samples commutable across all testing platforms. - Linearly related panel covering the pathological range. - Scoring based on Milan Model 3 performance specification. For more information: https://www.weqas.com/services/eqa/homocysteine/ or contact@weqas.com | ||||||
| Keywords | |||||||
| Product groups |
Health care / medical devices
|
||||||
| Testing fields |
Medical analysis
|
||||||
| Technical details | |||||||
|
|||||||
| Aims of the PT scheme | |||||||
| Target group of participants | The Homocysteine programme is available as part of a comprehensive suite of programmes to assess and monitor the performance of the Clinical Biochemistry laboratory’s repertoire of both core and esoteric tests used for the diagnosis and monitoring of disease. | ||||||
| Linked to specific legislation / standards | Accreditation by UKAS on the basis of ISO/IEC 17025, 17043 and 15195 | ||||||
| Additional, subsidiary aims | validation of testing methods | ||||||
| Number of participants | |||||||
| Accredited or otherwise reviewed by a 3rd party |
Accredited by UKAS on the basis of ISO/ IEC 17043 |
||||||
| Operation is commissioned / requested by | |||||||
| Fees and frequency | |||||||
| Participation fee | Fee dependent on number of participating sections and proximetry of testing methods. | ||||||
| Regularly operated | Yes (Frequency: Bimonthly. Samples: 3 x 0.5mL) | ||||||
| Year of first operation | 2004 | ||||||
| Contact details of the PT provider | |||||||
| Provider | Contact person | ||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Phone: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Phone: 44 (0) 29218 32884 Fax: Email: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
||||||
If you find any mistakes please contact the responsible EPTIS coordinator in United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.